The relationship between Lipoprotein A and other lipids with

prostate cancer risk: A multivariable Mendelian

3 randomisation study.

- 5 Anna Ioannidou¹, Eleanor L Watts², Aurora Perez-Cornago², Elizabeth A Platz³⁻⁵, Ian G Mills^{6,7,8},
- 6 Timothy J Key², Ruth C Travis², The PRACTICAL consortium, CRUK, BPC3, CAPS,
- 7 PEGASUS[†], Konstantinos K Tsilidis^{1,9*}, Verena Zuber^{1*}
- 9 Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London,
- 10 London, UK.

4

8

- ² Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford,
- 12 Oxford, UK.
- ³ Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore,
- 14 Maryland, USA
- ⁴ Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
- ⁵ Department of Urology and the James Buchanan Brady Urological Institute, Johns Hopkins
- 17 University School of Medicine, Baltimore, Maryland, USA
- ⁶ Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK
- ⁷ Patrick G Johnston Centre for Cancer Research (PGJCCR), Queen's University Belfast, Belfast,
- 20 UK
- ⁸ Centre for Cancer Biomarkers (CCBIO), University of Bergen, 5021 Bergen, Norway
- ^{9.} Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina,
- 23 Greece.

24

- 25 * contributed equally
- t Members from the PRACTICAL Consortium, CRUK, BPC3, CAPS and PEGASUS are provided
- in the Supplement (S1 file).
- 29 Funding: KKT was supported by Cancer Research UK (C18281/A29019). ELW was supported by
- 30 the NDPH Early Career Research Fellowship. APC is supported by a Cancer Research UK
- 31 Population Research Fellowship (C60192/A28516) and by the World Cancer Research Fund

- 32 (WCRF UK), as part of the Word Cancer Research Fund International grant programme
- 33 (2019/1953).

Abstract

35

36

41

Background

- Numerous epidemiological studies have investigated the role of blood lipids in prostate cancer
- 38 (PCa) risk though findings remain inconclusive to date. The ongoing research has mainly involved
- 39 observational studies which are often prone to confounding. This study aimed to identify the
- 40 relationship between genetically predicted blood lipid concentrations and PCa.

Methods and Findings

- Data for low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol,
- triglycerides (TG), apolipoprotein A (apoA) and B (apoB), lipoprotein A (Lp(a)) and PCa were
- 44 acquired from genome-wide association studies in UK Biobank and the PRACTICAL consortium,
- 45 respectively. We used a two-sample Mendelian randomisation (MR) approach with both univariable
- and multivariable (MVMR) models and utilised a variety of robust methods and sensitivity analyses
- 47 to assess the possibility of MR assumptions violation. No association was observed between
- 48 genetically predicted concentrations of HDL, TG, apoA and apoB and PCa risk. Genetically
- 49 predicted LDL concentration was positively associated with total PCa in the univariable analysis
- but adjustment for HDL, TG and Lp(a) led to a null association. Genetically predicted concentration
- of Lp(a) was associated with higher total PCa risk in the univariable ($OR_{weighted median}$ per sd = 1.091;
- 52 95% CI 1.028-1.157; P=0.004) and MVMR analyses after adjustment for the other lipid traits
- 53 (OR_{IVW} per sd = 1.068; 95% CI 1.005-1.134; P = 0.034). Genetically predicted Lp(a) was also
- associated with advanced (MVMR OR_{IVW} per sd = 1.078; 95% CI 0.999-1.163; P=0.055) and early
- 55 age onset PCa (MVMR OR_{IVW} per sd = 1.150; 95% CI 1.015,1.303; P = 0.028). Although multiple
- estimation methods were utilized to minimize the effect of pleiotropic traits, the presence of any
- 57 unmeasured pleiotropy cannot be excluded and may limit our findings.

Conclusions

58

- We observed that genetically predicted Lp(a) concentrations are associated with an increased PCa
- 60 risk. Future studies are required to understand the underlying biological pathways of this finding, as
- it may inform PCa prevention through Lp(a)-lowering strategies.

Introduction

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

Prostate cancer (PCa) is one of the most frequently diagnosed cancers in men [1] with 1,276,106 incident cases reported globally during 2018 [2]. There is high geographical heterogeneity of PCa incidence, which is reflected in a 40-fold difference in the age-adjusted incidence rates across the globe [3]. Several studies have argued that this could be attributed to the increased number of diagnoses in countries where the prostate specific antigen (PSA) screening is prevalent. Nevertheless, the basis for this heterogeneity remains poorly understood [1]. Given that PCa is also clinically heterogeneous, risk factors identified to date differ by disease aggressiveness [4]. In particular, established risk factors for total PCa are mainly non-modifiable, including older age, African-descent and genetics [5], whereas some potential risk factors for aggressive PCa include smoking, obesity [6], lower vitamin D and higher blood lipid levels [4] which are modifiable. Lipid-lowering therapies are cheap and well-established for lowering cardiovascular risk. Yet, there is no conclusive evidence that repurposed lipid-lowering drugs are effective for the prevention of PCa. It is therefore important to determine whether blood lipids increase PCa risk, especially lethal disease [7]. A meta-analysis of 14 prospective studies published in 2015 [10] did not observe significant associations between TC, HDL or LDL concentrations and risk of total or high-grade PCa, but high between-study heterogeneity was evident for most associations. Two meta-analyses have examined the role of statin use in PCa risk, and both observed inverse associations of statins and advanced PCa risk [11][12]. Nonetheless, whether these associations can be attributed to lower cholesterol itself or some other mechanism is unknown. Observational studies may suffer from unobserved confounding and reverse-causation [13], which could explain inconsistent findings among studies. Mendelian randomisation (MR) uses genetic variants as proxies for the exposures of interest and, if carefully conducted, can complement observational research [14] and support triangulation of evidence. That is because genetic variants are randomly allocated to offspring by parents and independently assorted during meiosis, which

minimise issues with reverse-causation and confounding [13,15]. In addition, most studies on lipids and PCa measure lipid levels only once which can lead to measurement error in the findings, whereas genetically predicted lipid levels capture lifelong expected levels. Previous MR research is limited to two studies that examined the role of HDL, LDL and TG in PCa risk overall and by disease stage and grade, and both reported null associations [16,17]. However, neither study adjusted for multiple lipid traits, which may have limited their findings given that different lipids are correlated and pleiotropic [18]. In this paper, we aim to identify whether genetically predicted lipid traits are associated with overall PCa risk, and in particular advanced and early age onset disease. We incorporated a univariable and multivariable MR (MVMR) framework to adjust for pleiotropic lipid effects, and examined the role of HDL, LDL and TG, as well as additional lipid-traits that have been underexamined to date, such as lipoprotein A (Lp(a)), apolipoprotein A (apoA) and apolipoprotein B (apoB).

Methods

Study populations

Blood Lipids Data

Genome-wide association (GWA) data for HDL, LDL, TG, Lp(a), apoA and apoB were available from UK Biobank, with information on over 13.7 million single-nucleotide polymorphisms (SNPs) [19]. Model adjustments in this UK Biobank GWAS included age, age^2, inferred_sex, interaction terms for age*inferred_sex and for age^2*inferred_sex, and the first 20 principal components. All measured serum biomarkers were approximately normally distributed except Lp(a), which was positively skewed. For consistency purposes, inverse rank-normalised data were used for all biomarkers. The heritability estimation from summary statistics (HESS) was applied in each of these lipids in a GWAS of Sinnott-Armstrong et al. [20] and heritability was reported as follows; HDL 36%, LDL 29%, TG 29%, Lp(a) 24%, apoA 31% and apoB 32% indicating strong genetic regulation of all lipid traits considered as exposures (Table S1). For the purpose of this research and

114 to match with the PCa GWAS, only European ancestry male participants were included 115 (N=167,020)116 **PCa Data** 117 Summary association statistics for PCa risk were acquired from the PRACTICAL consortium and 118 are based on Schumacher et al. [21]. The genotyping was performed using a custom array, namely 119 the OncoArray. A two-stage imputation was performed, using the SHAPEIT20 and IMPUTEv221. 120 For our analysis, we used total, advanced (metastatic or Gleason score (GS) >=8 or PSA>100 121 ng/mL or PCa death) and early age onset (PCa age <= 55) PCa. Study participants for total PCa 122 make up to a total of 79,166 cases and 61,106 controls, advanced PCa cases include 15,167 123 participants and 58,308 controls, whereas early age onset PCa includes 6,988 cases and 44,256 124 controls. All participants were of European ancestry. 125 **Assumptions** 126 The following assumptions were made for all our MR analyses and are described in combination for 127 both the univariable and MVMR approaches [22]. 128 1. Relevance: Genetic variants are associated with the exposure of interest in the case of 129 univariable MR, whereas for MVMR, they are associated with at least one of the exposures. 130 2. Exchangeability: Genetic variants are independent of all confounders of the exposure-131 outcome association for the univariable MR, whereas in the MVMR, variants are 132 independent of all confounders of each of the exposure-outcome associations. 133 3. Exclusion-restriction: Genetic variants are independent of the outcome given the 134 exposure/es and all the confounders. 135 Main MR analyses 136 All MR analyses were performed in R version 4.0.0. Due to the availability of exposure (blood 137 lipids) and outcome (PCa) data from two different sources, we used a two-sample MR study design. In the univariable MR, SNPs that satisfied genome-wide significance ($P < 5 \times 10^{-8}$) were selected 138 139 for each trait. After removing any inconsistencies with respect to the effect and non-effect alleles,

we harmonised the data so that the exposure and outcome datasets would have the same effect allele. We used the TwoSampleMR package version 0.5.4 to clump the data using a threshold of r2 < 0.001 to identify and remove any SNPs in high linkage disequilibrium (LD). All SNPs left after clumping were considered as the instrumental variables (IVs). We firstly ran the univariable analysis on all blood lipids for both total and advanced PCa, whilst for the early age onset PCa we focused our univariable analysis primarily on Lp(a). For the main estimation methods of the univariable analyses, we performed the inverse variance weighting (IVW) [23,24] and weighed median [13] approaches, and we additionally applied the MR-Egger [25] approach. To adjust for different lipid traits in our models, we performed a MVMR analysis. We chose to exclude apoA and apoB to avoid multicollinearity issues due to their high correlation with HDL and LDL, respectively $(r_{apoA,HDL}=0.978;\ P<2.2x10^{-6}/r_{apoB,LDL}=0.984;\ P<2.\ 2x10^{-6})$. The minimum p-value across the remaining lipids was computed and selection of SNPs was based on those that satisfied genome-wide significance through the minimum p-value $(P < 5 \times 10^{-8})$. After harmonisation was performed, we clumped the data based on a threshold of r2 < 0.001. The main estimation method performed was the IVW, while we additionally implemented the MR-Egger estimate [26] to control for any remaining unmeasured pleiotropy.

Sensitivity MR analyses

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

160

161

162

163

164

- As we observed a positive finding for Lp(a) and PCa outcomes, we performed the following sensitivity analyses in our univariable MR considering only Lp(a) as exposure for total, advanced and early age onset of PCa.
 - 1. Sensitivity analysis 1: As an attempt to increase the statistical power of the univariable MR, we used an eased clumping threshold of r2<0.01 and re-fitted the models based on a larger set of IVs.
 - 2. Sensitivity analysis 2: Variants that were used as IVs for Lp(a) in the Burgess et al. paper [27] based on a clumping threshold of r2<0.4, were separately fitted to the univariable models to validate findings on a different IV set. 43 IVs were initially proposed in the paper,

but only 28 of those were available in our current datasets and satisfied genome-wide significance. The univariable models were re-fitted based on these 28 IVs.

- 3. Sensitivity analysis 3: As the LPA gene (chromosome 6: 160,531,482-160,664,275) is the main gene associated with Lp(a) concentrations and explains about 70-90% of its variability [28], we selected variants located in the LPA gene based on a clumping threshold of r2<0.001 to represent strong biological instruments and potentially support the effect of Lp(a). Four such variants were identified and subsequently utilised as IVs.</p>
- 4. Sensitivity analysis 4: Additional robust estimation methods were utilised as part of our sensitivity analyses to control and/or test for horizontal pleiotropy. These included the MR-PRESSO [29] and contamination mixture [30].

As obesity may be considered a probable confounder for lipids and PCa [16], we also performed an additional adjustment for body mass index (BMI) in all the MVMR models, using genetic association data for BMI from UK Biobank [19]. Lp(a) is assembled in the liver [31], whereas liver function/disease has been proposed to influence PCa detection and outcomes [31-32]. Genetic associations for aspartate aminotransferase (AST) were thereby adjusted in a MVMR model including Lp(a) and total PCa. In addition, as kidney disease has been suggested to affect Lp(a) concentrations [34], and creatinine was previously associated with PCa risk [35], we performed another MVMR analysis using Lp(a), creatinine and total PCa to control for kidney function. Both genetic associations for AST and creatinine were acquired from UK Biobank [19]. Throughout our analyses, we considered significant estimates based on the 95% confidence level. We additionally estimated a Bonferroni-corrected p-value for the main univariable analyses on total and advanced PCa, to adjust for the multiple tests performed on each outcome. The total number of tests is reflected upon the number of different lipids we considered for each PCa outcome. Throughout the results section, nominally significant p-values are reported.

Results

190

191 Descriptive statistics for lipid measurements were available from UK Biobank [19] and can be seen 192 in S2 Table. Throughout this section we report results based solely on the IVW and weighted 193 median methods. Results from the additional methods we used, including MR-Egger (Table S3-S6), 194 MR-PRESSO and contamination mixture estimates (Table S3), and MVMR analyses adjusting for 195 BMI, AST and creatinine (Tables S6-9), can be found in the supplement and were in general in 196 agreement with the main analyses presented in the text below. The marginal associations of the 197 genetic instruments with exposures, outcomes and confounders/mediators are shown in Tables S10-198 15. 199 Univariable MR 200 **Total PCa** 201 The univariable MR analysis showed that genetically predicted HDL (OR_{IVW} = 0.994; 95% CI 202 =[0.942,1.051]; P=0.825), TG (OR_{IVW} =1.026; 95% CI = [0.961,1.105]; P=0.449), apoA 203 $(OR_{IVW} = 1.025; 95\% \text{ CI} = [0.970, 1.083]; P=0.372)$ and apoB $(OR_{IVW} = 1.026; 95\% \text{ CI} = 1.026)$ 204 0.961,1.094]; P=0.411) concentrations were not associated with total PCa risk (Table S4). In 205 contrast, the odds ratio of total PCa was 1.088 per standard deviation (sd) increase in genetically 206 predicted LDL (95% CI = [1.010, 1.162]; P=0.016). This association was however not supported by 207 the weighted median approach (OR=1.016; 95% CI = [0.942, 1.094]; P=0.669). This raised concerns 208 for potential pleiotropic effects present in our model and results were further assessed in the 209 multivariable model. 210 Genetically predicted Lp(a) had an insignificant association on total PCa as estimated from the IVW 211 $(OR_{IVW} = 1.066; 95\% \text{ CI} = [0.909, 1.249]; P=0.431)$ method (Table 1), but the odds ratio of total 212 PCa in the weighted median approach was 1.091 per sd increase in genetically predicted Lp(a) 213 (95% CI =[1.028,1.157]; P=0.004). Alteration of the clumping threshold in sensitivity analysis 1 214 resulted in a higher number of IVs fitted to our model, which supported a significant effect estimate

215 for Lp(a) in both the IVW ($OR_{IVW} = 1.076$; 95% CI = [1.016,1.114]; P=0.012) and weighted median 216 approaches ($OR_{weighted\ median} = 1.066$; 95% CI = [1.012,1.123]; P=0.016). Sensitivity analysis 2, 217 which included IVs according to the Burgess et al. paper [27], also supported a relationship between 218 genetically elevated Lp(a) and total PCa ($OR_{IVW} = 1.037$; 95% CI = [1.009,1.066]; P=0.010, 219 $OR_{weighted\ median} = 1.044$; 95% CI = [1.026,1.061]; P=6.58x10⁻⁷). Sensitivity analysis 3, which 220 involved variants located in the LPA gene only, supported an even stronger OR $(OR_{weighted\ median} = 1.439; 95\%\ CI = [1.280, 1.619];\ P=1.80x10^{-9})$ for total PCa per sd increase in 221 222 genetically predicted Lp(a). 223 Advanced PCa 224 The univariable MR analysis did not reveal any significant association between blood lipids and 225 advanced PCa risk (HDL; $OR_{IVW} = 0.977$; 95% CI = [0.905,1.051]; P =0.552, LDL; $OR_{IVW} = 1.067$; 226 95% CI = [0.970, 1.74]; P=0.191, TG; $OR_{IVW} = 1.004$; 95% CI = [0.923, 1.094]; P = 0.921, Lp(a); 227 $OR_{IVW} = 1.064$; 95% CI = 0.910,1.245]; P = 0.435, ApoA; $OR_{IVW} = 1.001$; 95% CI = [0.932,1.073], 228 P = 0.991, ApoB; $OR_{IVW} = 0.992$; 95% CI = [0.914, 1.073], P = 0.837) (Table 1, Table S5). 229 However, sensitivity analysis 2 for Lp(a), which included IVs of the Burgess et al. paper [27], 230 supported an association between genetically elevated Lp(a) ($OR_{weighted\ median} = 1.033$; 95% CI= 231 [1.001,1.065]; P=0.046) and advanced PCa. In addition, sensitivity analysis 3, which restricted to 232 variants in the LPA gene, supported an association between genetically elevated Lp(a) and advanced 233 PCa ($OR_{weighted\ median} = 1.388; 95\% \text{ CI} = [1.213, 1.590]; P=2.14x10^{-6}$). 234 Early age onset of PCa 235 Genetically predicted Lp(a) was associated with an increased risk of early age onset PCa in the 236 main univariable analysis ($OR_{weighted\ median} = 1.257$; 95% CI = [1.107,1.426]; P=4.00x10⁻⁴) 237 (Table 1). All univariable sensitivity analyses performed, confirmed a significant relationship 238 between genetically elevated Lp(a) and early age onset of PCa. [(Sensitivity analysis 1; OR_{IVW} =

1.215; 95% CI = [1.096, 1.349]; P= 2.03×10^{-4} , $OR_{weighted\ median} = 1.217$; 95% CI = [1.084,1.365];

- 240 P=0.001), (Sensitivity analysis 2; $OR_{IVW} = 1.076$; 95% CI = [1.027,1.126]; p-value=0.002,
- 241 $OR_{weighted\ median} = 1.079;\ 95\%\ CI = [1.036,1.124];\ P=3.20x10^{-4}),\ (Sensitivity\ analysis\ 3;$
- 242 $OR_{weighted\ median} = 1.502; 95\% \text{ CI} = [1.276, 1.770]; P=1.04x10^{-6})].$

		Method	OR	95% CI	P	Padjusted †
Total PCa	Main Analysis	IVW	1.066	[0.909,1.249]	0.431	1
		Weighted Median	1.091	[1.028,1.157]	0.004**	0.024*
	Sensitivity Analysis 1	IVW	1.076	[1.016,1.114]	0.012*	-
	•	Weighted Median	1.066	[1.012,1.123]	0.016*	-
	Sensitivity Analysis 2	IVW	1.037	[1.009,1.066]	0.010**	-
	•	Weighted Median	1.044	[1.026,1.061]	6.582x10 ⁻⁷ ***	-
	Sensitivity Analysis 3	IVW	1.228	[0.960,1.570]	0.104	-
	•	Weighted Median	1.439	[1.280,1.619]	1.799x10 ⁻⁹ ***	-
					0.405	
Advanced PCa	Main Analysis	IVW	1.064	[0.910,1.245]	0.435	1 0.948
		Weighted Median	1.071	[0.973,1.179]	0.158	0.948
	Sensitivity Analysis 1	IVW	1.051	[0.981,1.127]	0.158	-
		Weighted Median	1.051	[0.974,1.135]	0.197	-
	Sensitivity Analysis 2	IVW	1.024	[0.992,1.058]	0.139	-
		Weighted Median	1.033	[1.001,1.065]	0.046*	-
	Sensitivity Analysis 3	IVW	1.226	[0.957,1.570]	0.107	-
	-	Weighted Median	1.388	[1.213,1.590]	2.138x10 ⁻⁶ ***	•
		*****			0.400	
Early age onset PCa	Main Analysis	IVW	1.169	[0.927,1.473]	0.188	-
		Weighted Median	1.257	[1.107,1.426]	4.000x10 ⁻⁴ ***	-
	Sensitivity Analysis 1	IVW	1.215	[1.096,1.349]	2.028x10 ⁻⁴ ***	-
	-	Weighted Median	1.217	[1.084,1.365]	0.001***	-
	Sensitivity Analysis 2	IVW	1.076	[1.027,1.126]	0.002**	-
		Weighted Median	1.079	[1.036,1.124]	3.201x10 ⁻⁴ ***	
	Sensitivity Analysis 3	IVW	1.481	[0.907,2.418]	0.116	-
		Weighted			1.038x10 ⁻⁶ ***	

Table 1. Univariable estimates of genetically predicted Lp(a) on each PCa outcome.

Multivariable MR

As an attempt to control for pleiotropic pathways that could arise from the relationship between different lipid traits, we incorporated a MVMR model including Lp(a), HDL, LDL and TG jointly as exposures for each PCa outcome. The significant association observed between genetically predicted LDL and total PCa in univariable MR attenuated in the multivariable MR model and was no longer significant (OR = 1.052; 95% CI = [0.973,1.134]; P=0.183) (Table 2). However, after adjusting for HDL, LDL and TG, genetically predicted Lp(a) remained significantly and positively associated with total PCa (OR = 1.068; 95% CI = [1.005,1.134]; P=0.034). Additional adjustment for BMI led to an almost unaltered OR for total PCa risk per sd increase in genetically predicted Lp(a) (OR = 1.066; 95% CI = [1.008,1.129]; P=0.026) (Table S7). Genetically predicted Lp(a) was associated at borderline significance with advanced PCa after adjusting for multiple lipid traits (OR= 1.078; 95% CI = [0.999,1.163]; P=0.055). Additional adjustment for BMI led to an OR of 1.075 (95% CI: [1,1.155]; P=0.050). Genetically elevated Lp(a) remained significantly associated with early age onset of PCa (OR= 1.150; 95% CI = [1.015,1.303]; P = 0.028), in agreement with the univariable MR analysis. Adjustment for BMI yielded a similar effect of 1.155 (95% CI = [1.029,1.297]; P = 0.015). IVW estimates for all lipids from the MVMR can be seen in Table 2

Results are based on the inverse variance weighting (IVW) and weighted median estimation methods. ORs for each PCa outcome are reported per sd increase in genetically predicted Lp(a). The main analysis included IVs based on a clumping threshold of 0.001, sensitivity analysis 1 is based on an eased clumping threshold of 0.01, sensitivity analysis 2 is based on a different IV set from another paper and finally sensitivity analysis 3 is based upon variants located in the *LPA* gene. Associations of P<0.05 are shown in bold. $P \in (0.05,0.1]$, * $P \in (0.01,0.05]$, ** $P \in (0.001,0.01]$, *** $P \in (0.0001]$. † Padjusted is the Bonferroni corrected p-value, taking into account the total number of tests performed in the main analysis for total and advanced PCa. This reflects a total of 5 univariable analyses performed on each outcome (one for each lipid). For the early age onset of PCa only Lp(a) was fitted to the model

below, whereas the IVW BMI-adjusted results can be found in Table S7. We compared the multivariable Lp(a) estimates from all the analyses performed on total, advanced and early age

and thus no correction was applied to the p-value.

onset PCa with the univariable estimates and additional sensitivity analyses through a panel of three distinct forest plots (Fig 1). IVs according to variants in the *LPA* gene (Sensitivity Analysis 3), supported the strongest effect between genetically predicted Lp(a) concentrations and each PCa outcome.

MVMR

263

264

265

266

267

268

269

270

271

272

284

Table 2.

273 each PCa results for OR 95% CI P Biomarker Total PCa HDL 1.009 [0.946,1.077] 0.775 274 outcome. LDL 1.052 0.183 [0.973, 1.134]TG 1.026 [0.953,1.106] 0.485 275 Lp(a) 1.068 [1.005,1.134] 0.034* 276 Advanced HDL 0.872 0.993 [0.917,1.077] 277 *PCa* LDL 1.007 [0.916,1.106] 0.892 278 TG 1.003 0.952 [0.914,1.101] 279 Lp(a) 1.078 [0.999,1.163] 0.055. 280 HDL 0.732 Early age 1.024 [0.894, 1.174]281 onset PCa LDL 0.192 1.112 [0.948,1.305] 282 TG 1.062 0.450 [0.908,1.242] 0.028* Lp(a) 1.150 [1.015,1.303] 283

Each estimate (OR) is based on the multivariable IVW method and represents the direct effect of the risk factor on the respective outcome after controlling for the other three biomarkers in MVMR. ORs are reported per sd increase in the respective biomarker. Genetically elevated Lp(a) is significantly associated with total and early age onset PCa, whereas it is associated also at borderline significance with advanced PCa. Associations of P<0.05 are shown in bold. $P \in (0.05,0.1]$, *P $\in (0.01,0.05]$, **P $\in (0.001,0.01]$, ***P $\in (0.001,0.001]$.




Fig 1. Forest plots of the Lp(a) effects observed in different analyses based on each PCa type. The main and sensitivity analyses estimates are based on the weighted median approach, whereas MVMR includes the IVW estimates. Sensitivity analyses 1-3 refer to the univariable models. Sensitivity analysis 1 is based on an eased clumping threshold of 0.01, sensitivity analysis 2 includes an IV set based on another paper and finally sensitivity analysis 3 is based upon variants located in the *LPA* gene. Each square represents the OR for each PCa outcome, reported per sd increase in the biomarker, with the 95% CI represented by the error bars.

Discussion

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

Our MR analyses provide evidence that genetically predicted Lp(a) concentration is associated with risk of total and early age onset PCa and suggestive evidence for an association with advanced PCa. The majority of the different methods we used for our univariable analyses agreed for total and early age onset PCa. Lp(a) was only significantly associated with advanced PCa in two of the univariable sensitivity analyses. IVs located in the LPA gene supported the strongest and most significant Lp(a) associations for total, advanced and early age onset PCa. Given the strong regulation of Lp(a) levels by the LPA gene region [28], the latter findings are based on strong instruments with a clear biological function. Adjustment for multiple lipid traits and BMI in the MVMR models, further supported a significant association of genetically predicted Lp(a) on total, advanced and early age onset PCa. The null associations observed for genetically predicted HDL on total PCa agree with findings from two previous MR analyses [16][17], and the null findings for TG are also supported in the Bull et al. [16] paper. In our analysis, there was some evidence for a significant LDL association with total PCa risk, though this was likely a false indication due to pleiotropy, as suggested by the MVMR model which indicated no association with LDL. As Lp(a) includes an LDL component [36], the attenuation of LDL to the null in the MVMR could be attributed to independent actions of Lp(a) itself, as we did not observe any association between other Lp(a) components and PCa risk. Alternative explanations are that Lp(a) concentrations are less affected by statins compared to LDL [37], thus genetically predicted Lp(a) may be more accurate for current actual levels than genetically predicted LDL, or that the association for Lp(a) dominates over LDL due to the high between-person variability of Lp(a) [20]. The authors of the Bull et al. paper [16] suggested a potential role of LDL and TG in advanced/high-grade PCa; our findings for LDL and TG in advanced PCa risk are not in agreement with theirs. Our analyses included adjustment for multiple lipid traits in contrast with the previously mentioned papers, which we believe plays a vital role in MR analysis modelling blood lipids, given the high correlation between them. As far as we are

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

aware, no previous MR study has investigated the role of apoA and apoB in PCa risk. Our null results are nonetheless in agreement with observational studies by Katzke et al [8], which involved the prospective EPIC-Heidelberg cohort and Borgquist et al [38], which was based on the prospective Malmö Diet and Cancer Study (MDCS). To the best of our knowledge, no previous MR study has examined the role of Lp(a) in PCa risk. The positive association observed for Lp(a) in total PCa was supported by the observational study of Katzke et al. [8]. Results showed that top vs. bottom quartile levels of Lp(a) were associated with a 47% higher risk of PCa (OR=1.47; 95% CI = 1.06-2.04). Wang F et al. [39], another observational study, examined the role of Lp(a) in high-risk PCa via a multivariable regression adjusted for age, BMI, hypertension, diabetes, coronary artery disease, and lipid-lowering drugs. They observed that high Lp(a) levels were positively associated ($OR_{O4 \text{ vs. O1}} = 2.687$; 95% CI = 1.113-6.491; P = 0.028) with high-risk PCa, which agrees with our findings for advanced PCa in the MVMR analysis. In addition, a recent large prospective cohort among 211,754 men in UK Biobank [40] observed a suggestive positive association between Lp(a) and PCa risk (hazard ratio_{per SD} =1.02; 95% CI: [0.99,1.06]). Our literature review did not reveal any studies investigating the role of Lp(a) in early age onset PCa. A range of different biological mechanisms have been proposed to explain pro-cancer effects of cholesterol at the cellular level, including cell proliferation, inflammation, membrane organization, and steroidogenesis [41]. It is unclear whether total cholesterol or any lipoprotein particle is the causal factor, and the potential pathophysiological mechanisms of Lp(a) have not been well-studied. However, emerging evidence from the cardiovascular literature supports pleiotropic functions of Lp(a) and complex mediation pathways with other lipid particles [42]. Lp(a) is highly heritable (heritability=24%) [20], with the majority of individuals having low Lp(a) levels. However, African Americans which are known to have the highest risk for PCa, tend to also have higher circulating Lp(a) levels [28]. It has been previously observed that mean Lp(a) concentrations for African Americans are 106 (60-180) nmol/l, whereas Caucasians such as non-Hispanic whites have mean

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

Lp(a) concentrations of 24 (7.2-79.2) nmol/l [43]. Although the exact explanation behind ethnic discrepancies in PCa is currently unknown, it has been hypothesised that access to health care may play a partial role in this. Yet, given that disparities in PCa risk are apparent regardless of cancer detection issues, it is likely that biological factors are key drivers of this phenomenon [44]. Two recent papers have further provided evidence of a different immune response [45] and inflammatory signalling [46] for African Americans vs. Caucasians, which can be linked to their poorer PCa prognosis. Considering Lp(a) as a modifier of the immune/inflammatory response [47], the increased Lp(a) concentrations in African Americans and our observed association between genetically elevated Lp(a) and PCa, we hypothesise that Lp(a) may partially account for some of the observed discrepancies in PCa risk by ethnicity. Future large-scale genomic studies in African ancestry populations [48] would be required to evaluate the hypothesis that Lp(a) can explain discrepancies in PCa risk by race. We note several limitations to our research. Currently, there is no direct way to prove that the second and third MR assumptions hold and as such, violations would result in biased MR estimates. A large number of robust methods and sensitivity analyses were used to probe into potential violations mainly due to horizontal pleiotropy, but its presence cannot be excluded. The samples analysed for our main MR analyses were restricted to Europeans to avoid issues with heterogeneity, which is required for a two-sample MR [49]. However, this may affect generalisability of the results, which are restricted to those of European ancestry. The number of variants associated with Lp(a) was limited in comparison to other lipids. Initially, 5894 variants were identified to be associated with Lp(a) at GWAS significance, whereas all other lipids had more than 10,000 associated variants. This then resulted in a final sample size of 10 variants due to LD clumping in the main univariable analysis, which may have decreased our statistical power. However, after relaxing the LD clumping threshold in our sensitivity analyses, we included more variants, the findings of which corroborated the main results. In addition, some previous observational studies have suggested potential threshold effects for cholesterol concentrations and PCa [50,51], which

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

cannot be studied in two-sample MR with summary-level data, and future one-sample MR studies are warranted. Apart from the caveats in our study, there are also several strengths that should be noted. We used an MR study design, in which the outcome of interest is compared between genotypes, analogous to that between treatment and placebo groups in a randomised controlled trial. However, inference should be made with great caution as alterations of genetically predicted risk factors are not identical to those due to a drug or dietary intervention [52]. Secondly, as lipids are dependent on each other for their main functionalities [18], it is important to control for pleiotropic pathways that may arise from these dependencies. One method to do so, is via the use of MVMR which allows to include genetic information on exposures that may correlate with each other into a joint multivariable model [53] and our study forms the first such MVMR conducted to investigate the relationship between various lipid traits and PCa risk. Thirdly, the use of UK Biobank data allowed us to include information on underexamined lipid traits such as Lp(a), apoA and apoB, in comparison to previous PCa studies which mainly considered HDL, LDL and TG. In addition, we have sex-specific genetic associations and this allowed us to work with male-specific data which are more relevant to PCa. Finally, our analyses are based on large sample sizes which were acquired from UK Biobank [19] and the PRACTICAL consortium [21]. In summary, findings from this study point towards a positive association between genetically predicted Lp(a) concentrations and risk of total, advanced and early age onset PCa. Screening for high Lp(a) concentrations could possibly be investigated in the future to identify high-risk groups for PCa. Given that Lp(a) concentrations depend significantly on genetics [54], modification of Lp(a) levels may be achieved by developing Lp(a)-lowering drugs [55] that might be on the horizon. A personalised approach in repurposing lipid drugs that target Lp(a) directly for high-risk individuals could consequently be considered, upon replication of our findings, to study their effectiveness against PCa prevention. The mechanisms behind the observed association remain however unclear given the uncertainty underlining the pleiotropic physiological functions of the

- 395 LPA gene itself, which controls about 70-90% of the Lp(a) variability [36,54]. Further research into
- 396 this complex gene such as colocalization analysis would be required to understand more of its
- 397 functionality and consequently its role in PCa risk.

References

- 399 1. Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019;10(2):63–89.
- 400 2. Cancer R. Global cancer observatory [Internet]. [cited 2020 Jun 26]. Available from:
- 401 https://gco.iarc.fr/
- 402 3. Loda M, Mucci LA, Mittelstadt ML, Van Hemelrijck M, Cotter MB. Pathology and
- 403 epidemiology of cancer. In: Pathology and Epidemiology of Cancer. 2016. p. 1–670.
- 404 4. Pernar CH, Ebot EM, Wilson KM, Mucci LA. The Epidemiology of Prostate Cancer. Cold
- Spring Harb Perspect Med. 2018;8(12).
- Tse LA, Ho WM, Wang F, He YH, Ng CF. Environmental risk factors of prostate cancer: a
- case-control study. Hong Kong Med J = Xianggang yi xue za zhi. 2018;24(4):30–3.
- 408 6. Moyad MA. Preventing aggressive prostate cancer with proven cardiovascular disease
- 409 preventive methods. Asian J Androl. 2015;17(6):874–7.
- 410 7. Hurwitz LM, Agalliu I, Albanes D, Barry KH, Berndt SI, et al. Recommended Definitions of
- 411 Aggressive Prostate Cancer for Etiologic Epidemiologic Research. JNCI J Natl Cancer Inst.
- 412 2021;113(6):727–34.
- 413 8. Katzke VA, Sookthai D, Johnson T, Kühn T, Kaaks R. Blood lipids and lipoproteins in
- relation to incidence and mortality risks for CVD and cancer in the prospective EPIC-
- Heidelberg cohort. BMC Med. 2017;15(1).
- 416 9. Jamnagerwalla J, Howard LE, Allott EH, Vidal AC, Moreira DM, Castro-Santamaria R, et al.
- 417 Serum cholesterol and risk of high-grade prostate cancer: Results from the REDUCE study.
- 418 Prostate Cancer Prostatic Dis. 2018;21(2):252–9.
- 419 10. Yu Peng L, Yu Xue Z, Fei LP, Cheng C, Ya Shuang Z, Da Peng L, et al. Cholesterol levels

- in blood and the risk of prostate cancer: A meta-analysis of 14 prospective studies. Cancer
- 421 Epidemiol Biomarkers Prev. 2015;24(7):1086–93.
- 422 11. Bansal D, Undela K, D'Cruz S, Schifano F. Statin Use and Risk of Prostate Cancer: A Meta-
- 423 Analysis of Observational Studies. PLoS One. 2012;7(10).
- 12. Tan P, Wei S, Tang Z, Gao L, Zhang C, Nie P, et al. LDL-lowering therapy and the risk of
- prostate cancer: A meta-analysis of 6 randomized controlled trials and 36 observational
- 426 studies. Sci Rep. 2016;6.
- 427 13. Yarmolinsky J, Wade KH, Richmond RC, Langdon RJ, Bull CJ, Tilling KM, et al. Causal
- inference in cancer epidemiology: What is the role of mendelian randomization? Cancer
- 429 Epidemiol Biomarkers Prev. 2018;27(9):995–1010.
- 430 14. Davies NM, Holmes M V., Davey Smith G. Reading Mendelian randomisation studies: A
- 431 guide, glossary, and checklist for clinicians. BMJ. 2018;362.
- 432 15. Zheng J, Baird D, Borges M-C, Bowden J, Hemani G, Haycock P, et al. Recent
- Developments in Mendelian Randomization Studies. Curr Epidemiol Reports.
- 434 2017;4(4):330–45.
- 435 16. Bull CJ, Bonilla C, Holly JMP, Perks CM, Davies N, Haycock P, et al. Blood lipids and
- prostate cancer: a Mendelian randomization analysis. Cancer Med. 2016;5(6):1125–36.
- 437 17. Adams CD, Richmond R, Santos Ferreira DL, Spiller W, Tan V, Zheng J, et al. Circulating
- 438 metabolic biomarkers of screen-detected prostate cancer in the ProtecT study. Cancer
- 439 Epidemiol Biomarkers Prev. 2019;28(1):208–16.
- 440 18. Dominiczak MH, Caslake MJ. Apolipoproteins: Metabolic role and clinical biochemistry
- 441 applications. Ann Clin Biochem. 2011;48(6):498–515.
- 442 19. Lab N. GWAS of UK Biobank biomarker measurements Neale lab [Internet]. 2020 [cited
- 443 2020 Aug 16]. Available from: http://www.nealelab.is/blog/2019/9/16/biomarkers-gwas-
- 444 results
- 445 20. Sinnott-Armstrong N, Tanigawa Y, Amar D, Mars N, Benner C, Aguirre M, et al. Genetics

- of 35 blood and urine biomarkers in the UK Biobank. Nat Genet. 2021;
- 447 21. Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, et al.
- Association analyses of more than 140,000 men identify 63 new prostate cancer
- susceptibility loci. Nat Genet. 2018;50(7):928–36.
- 450 22. Labrecque J, Swanson SA. Understanding the Assumptions Underlying Instrumental
- Variable Analyses: a Brief Review of Falsification Strategies and Related Tools. Curr
- 452 Epidemiol Reports. 2018;5(3):214–20.
- 453 23. Rees JMB, Wood AM, Dudbridge F, Burgess S. Robust methods in Mendelian
- randomization via penalization of heterogeneous causal estimates. PLoS One. 2019;14(9).
- 455 24. Burgess S, Butterworth A TS. Mendelian randomization analysis with multiple genetic
- variants using summarized data. Genet Epidemiol. 2013;37(7):658–65.
- 457 25. Bowden J, Fabiola Del Greco M, Minelli C, Smith GD, Sheehan NA, Thompson JR.
- 458 Assessing the suitability of summary data for two-sample mendelian randomization analyses
- using MR-Egger regression: The role of the I 2 statistic. Int J Epidemiol. 2016;45(6):1961–
- 460 74.
- 461 26. Rees JMB, Wood AM, Burgess S. Extending the MR-Egger method for multivariable
- Mendelian randomization to correct for both measured and unmeasured pleiotropy. Stat Med.
- 463 2017;36(29):4705–18.
- 464 27. Burgess S, Ference BA, Staley JR, Freitag DF, Mason AM, Nielsen SF, et al. Association of
- 465 LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering
- therapies: A mendelian randomization analysis. JAMA Cardiol. 2018;3(7):619–27.
- 467 28. Kronenberg F, Utermann G. Lipoprotein(a): Resurrected by genetics. J Intern Med.
- 468 2013;273(1):6–30.
- 469 29. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in
- causal relationships inferred from Mendelian randomization between complex traits and
- 471 diseases. Nat Genet. 2018;50(5):693–8.

- 472 30. Burgess S, Foley CN, Allara E, Staley JR, Howson JMM. A robust and efficient method for
- 473 Mendelian randomization with hundreds of genetic variants. Nat Commun. 2020;11(1).
- 474 31. Maranhão RC, Carvalho PO, Strunz CC, Pileggi F. Lipoprotein (a): Structure,
- pathophysiology and clinical implications. Arq Bras Cardiol. 2014;103(1):76–84.
- 476 32. Wang A, Lazo M, Ballentine Carter H, Groopman JD, Nelson WG, Platz EA. Association
- between Liver Fibrosis and Serum PSA among U.S. Men: National Health and Nutrition
- Examination Survey (NHANES), 2001-2010. Cancer Epidemiol Biomarkers Prev.
- 479 2019;28(8):1331–8.
- 480 33. Bañez LL, Loftis RM, Freedland SJ, Presti JC, Aronson WJ, Amling CL, et al. The influence
- of hepatic function on prostate cancer outcomes after radical prostatectomy. Prostate Cancer
- 482 Prostatic Dis. 2010;13(2):173–7.
- 483 34. Hopewell JC, Haynes R, Baigent C. The role of lipoprotein (a) in chronic kidney disease. J
- 484 Lipid Res. 2018;59(4):577–85.
- 485 35. Weinstein SJ, Mackrain K, Stolzenberg-Solomon RZ, Selhub J, Virtamo J, Albanes D.
- Serum creatinine and prostate cancer risk in a prospective study. Cancer Epidemiol
- 487 Biomarkers Prev. 2009;18(10):2643–9.
- 488 36. Schmidt K, Noureen A, Kronenberg F, Utermann G. Structure, function, and genetics of
- 489 lipoprotein (a). J Lipid Res. 2016;57(8):1339–59.
- 490 37. Van Capelleveen JC, Van Der Valk FM, Stroes ESG. Current therapies for lowering
- 491 lipoprotein (a). J Lipid Res. 2016;57(9):1612–8.
- 492 38. Borgquist S, Butt T, Almgren P, Shiffman D, Stocks T, Orho-Melander M, et al.
- 493 Apolipoproteins, lipids and risk of cancer. Int J Cancer. 2016;138(11):2648–56.
- 494 39. Wang FM, Zhang Y. High Lipoprotein(a) Level Is Independently Associated with Adverse
- 495 Clinicopathological Features in Patients with Prostate Cancer. Dis Markers. 2019;2019.
- 496 40. Perez-Cornago A, Fensom GK, Andrews C, Watts EL, Allen NE, Martin RM, et al.
- Examination of potential novel biochemical factors in relation to prostate cancer incidence

- 498 and mortality in UK Biobank. Br J Cancer. 2020;123(12):1808–17.
- 499 41. Murtola TJ, Syvälä H, Pennanen P, Bläuer M, Solakivi T, Ylikomi T, et al. The importance
- of LDL and Cholesterol metabolism for prostate epithelial cell growth. PLoS One. 2012;7(6).
- 501 42. Boffa MB, Koschinsky ML. Oxidized phospholipids as a unifying theory for lipoprotein(a)
- and cardiovascular disease. Nat Rev Cardiol. 2019;16(5):305–18.
- 503 43. Enkhmaa B, Anuurad E, Berglund L. Lipoprotein (a): Impact by ethnicity and environmental
- and medical conditions. J Lipid Res. 2016;57(7):1111–25.
- 505 44. Rebbeck TR. Prostate cancer disparities by race and ethnicity: From nucleotide to
- neighborhood. Cold Spring Harb Perspect Med. 2018;8(9).
- 507 45. Thomas JK, Mir H, Kapur N, Singh S. Racial di□erences in immunological landscape
- modifiers contributing to disparity in prostate cancer. Cancers (Basel). 2019;11(12).
- 509 46. Tang W, Wallace TA, Yi M, Magi-Galluzzi C, Dorsey TH, Onabajo OO, et al. IFNL4-ΔG
- allele is associated with an interferon signature in tumors and survival of African-American
- men with prostate cancer. Clin Cancer Res. 2018;24(21):5471–81.
- 512 47. Orsó E, Schmitz G. Lipoprotein(a) and its role in inflammation, atherosclerosis and
- 513 malignancies. Clin Res Cardiol Suppl. 2017;12:31–7.
- 514 48. Fatumo S. The opportunity in African genome resource for precision medicine.
- 515 EBioMedicine. 2020;54.
- 516 49. Haycock PC, Burgess S, Wade KH, Bowden J, Relton C, Smith GD. Best (but oft-forgotten)
- 517 practices: The design, analysis, and interpretation of Mendelian randomization studies. Am J
- 518 Clin Nutr. 2016;103(4):965–78.
- 519 50. Platz EA, Till C, Goodman PJ, Parnes HL, Figg WD, Albanes D, et al. Men with low serum
- 520 cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate
- 521 cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 2009;18(11):2807–13.
- 522 51. Platz EA, Clinton SK, Giovannucci E. Association between plasma cholesterol and prostate
- 523 cancer in the PSA era. Int J Cancer. 2008;123(7):1693–8.

524 52. Burgess S, Butterworth A, Malarstig A, Thompson SG. Use of Mendelian randomisation to 525 assess potential benefit of clinical intervention. BMJ. 2012;345. 526 53. Zuber V, Colijn JM, Klaver C, Burgess S. Selecting causal risk factors from high-throughput 527 experiments using multivariable mendelian randomization. bioRxiv. 2018; 528 54. Kronenberg F. Human Genetics and the Causal Role of Lipoprotein(a) for Various Diseases. 529 Cardiovasc Drugs Ther. 2016;30(1):87–100. 530 55. Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, et al. Antisense 531 oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two 532 randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet. 533 2016;388(10057):2239–53. **Supporting information** 534 535 S1 Table. Heritability of each blood lipid as estimated in a GWAS of Sinnott-Armstrong et al 536 [20]. The estimates represent total heritability and the methodology followed was the Heritability 537 estimation summary statistics (HESS). The number of SNPS fitted in each model for the main 538 univariable analysis is also reported. 539 **S2 Table. Descriptive statistics of each blood lipid.** Lp(a) is positively skewed, whereas the rest 540 of the lipids are approximately normally distributed. Measurements are based on all samples (both 541 sexes) in UK Biobank [19]. 542 S3 Table, MR-Egger, MR-Presso and Contamination Mixture estimates for Lp(a) on each 543 **PCa outcome.** The contamination mixture method may indicate two distinct CIs associated with a 544 single estimate. Associations of P<0.05 are shown in bold. $P \in (0.05, 0.1], P \in (0.01, 0.05], P \in (0.01, 0.05], P \in (0.01, 0.05]$ 545 (0.001,0.01], *** $P \in (0,0.001]$. 546 S4 Table. Univariable MR estimates for each lipid on total PCa. Genetically elevated LDL is 547 significantly associated with total PCa only through the IVW approach, whereas the pleiotropy548 robust methods do not support this association. Associations of P<0.05 are shown in bold. $P \in \mathbb{R}$ (0.05,0.1], *P \in (0.01,0.05], **P \in (0.001,0.01], ***P \in (0,0.001]. 549 550 S5 Table. Univariable MR estimates for each lipid on advanced PCa. None of these lipids are 551 associated with advanced PCa. 552 S6 Table. MR-Egger estimates for Lp(a) and each PCa outcome. Sensitivity Analyses refer to 553 the univariable MR and are as follows; Sensitivity Analysis 1 includes variants according to an 554 eased clumping threshold of r2<0.01, sensitivity analysis 2 includes SNPs for Lp(a) according to a 555 different IV set, whereas sensitivity analysis 3 is based on variants included in the LPA gene. 556 Associations of P<0.05 are shown in bold. $P \in (0.05, 0.1], P \in (0.01, 0.05], P \in (0.001, 0.01],$ 557 *** $P \in (0,0.001]$. 558 S7 Table. IVW estimates from the MVMR model adjusted for BMI. Genetically elevated Lp(a) 559 is associated with overall, advanced and early onset of PCa in these models. Associations of P<0.05 560 are shown in bold. $P \in (0.05, 0.1], *P \in (0.01, 0.05], **P \in (0.001, 0.01], ***P \in (0, 0.001].$ 561 S8 Table. IVW and MR-Egger estimates from the total PCa MVMR model adjusted for Lp(a) 562 and AST. Genetically elevated Lp(a) is significantly associated with total PCa through the IVW 563 method. Associations of P<0.05 are shown in bold. $P \in (0.05, 0.1], P \in (0.01, 0.05], P \in (0.01, 0.05], P \in (0.01, 0.05]$ 564 (0.001,0.01], *** $P \in (0,0.001]$. 565 S9 Table. IVW and MR-Egger estimates from the total PCa MVMR model adjusted for Lp(a) 566 and creatinine. Genetically elevated Lp(a) is significantly associated with total PCa through the 567 IVW method and associated at borderline significance with total PCa with the MR-Egger approach. 568 Associations of P<0.05 are shown in bold. $P \in (0.05,0.1], P \in (0.01,0.05], P \in (0.001,0.01], P \in (0.$ 569 *** $P \in (0,0.001]$. 570 S10 Table. Association between SNPs and each lipid biomarker and BMI. The following list 571 includes IVs used in the main analysis, MVMR (adjusted for HDL,LDL,TG,Lp(a) and BMI) and 572 sensitivity analyses 1-4.

573 S11 Table. Association between SNPs and total PCa. The following list includes IVs used in the 574 main analysis, MVMR (adjusted for HDL,LDL,TG,Lp(a) and BMI) and sensitivity analyses 1-4. 575 S12 Table. Association between SNPs and advanced PCa. The following list includes IVs used 576 in the main analysis, MVMR (adjusted for HDL,LDL,TG,Lp(a) and BMI) and sensitivity analyses 577 1-4. 578 S13 Table. Association between SNPs and early age onset PCa. The following SNPs include IVs 579 used in the main analysis, MVMR (adjusted for HDL,LDL,TG,Lp(a) and BMI) and sensitivity 580 analyses 1-4. 581 S14 Table. Association between SNPs, Lp(a), AST and total PCa. The following SNPs include 582 IVs used in the additional MVMR analysis on Lp(a), AST and total PCa only. 583 S15 Table. Association between SNPs, Lp(a), creatinine and total PCa. The following SNPs 584 include IVs used in the additional MVMR analysis on Lp(a), creatinine and total PCa only. 585 S1 File. Members from the PRACTICAL Consortium, CRUK, BPC3, CAPS and PEGASUS 586